Sponsored by
The Bottom Line Upfront 💡
J&J $JNJ ( ▲ 0.85% ) absorbed a brutal STELARA patent cliff and still grew, thanks to a red-hot oncology franchise. The stock looks undervalued at ~$253 — but talc litigation and a 2029 DARZALEX cliff are real risks. A buy for patient investors who can tune out the noise.
Sponsorship
Stop overpaying! Get Tello's same reliable 5G network for under $25
Tired of paying for perks you don't actually use? With Tello, you can build your own plan and get the same reliable 5G coverage for way less.
Strata Layers Chart
Layer 1: The Business Model 🏛️
Founded in 1887 — yes, before the automobile — J&J has had a lot of time to figure out healthcare. Today it operates through two segments:
Innovative Medicine (64% of revenue, $60.4B) is the pharmaceutical engine: cancer treatments, immunology biologics, antidepressants, blood thinners. Expensive to develop, but once approved and patented the margins are chef’s kiss — 36.9% pre-tax profit on segment sales. The catch? Patents expire, and generic/biosimilar competitors then swarm like bargain hunters at a clearance sale.
MedTech (36% of revenue, $33.8B) makes the devices doctors use in procedures: heart rhythm devices, hip and knee implants, surgical staplers, ACUVUE contact lenses, and Impella heart pumps. Lower margins (12.2% pre-tax), but more stable — people need knee replacements regardless of the economy.
How they measure success: operational sales growth (stripping out currency noise), segment income-before-tax margins, pipeline approvals, and new products as a % of sales (currently 25% from the last five years ↗️).
Key Takeaway: J&J is a two-engine machine — a high-margin pharma business funding a steady device business — held together by 138,200 employees and a 137-year-old sense of purpose.
Layer 2: Category Position 🏆
J&J competes against the biggest names in healthcare: Roche, Pfizer, Merck, AbbVie, Amgen, and Stryker (devices). It’s not the scrappy underdog — it’s the incumbent everyone wants to dethrone.
Where it’s winning 🏅:
Oncology is on fire ↗️ — $25.4B in sales, up 22.1%. DARZALEX (multiple myeloma) hit $14.4B, still growing 23%. CARVYKTI (CAR-T therapy) nearly doubled to $1.9B.
TREMFYA (psoriasis/IBD) grew 40.5% to $5.2B, stepping up as STELARA’s heir apparent.
Cardiovascular MedTech grew 15.8%, powered by Shockwave (acquired 2024) and Abiomed’s Impella heart pumps.
Where it’s getting punched 🥊:
STELARA — the former cash cow — cratered 41.3% ↘️ to $6.1B as biosimilars flooded the market. A known risk, but watching $4.3B in annual revenue evaporate in one year still stings.
Orthopaedics grew just 1.1% ↗️, hurt by China pricing pressure and restructuring. J&J plans to spin it off as a separate company, DePuy Synthes — essentially admitting it fits better elsewhere.
Key Takeaway: J&J is winning where it matters most (oncology, cardiovascular), losing where expected (STELARA biosimilars), and pruning the slow-growth branches.
Layer 3: Show Me The Money! 📈
Revenue breakdown:
🇺🇸 U.S.: $53.8B (57%), growing 6.9% ↗️
🌍 International: $40.4B (43%), growing 5.0% ↗️
Europe grew 6.5% (favorable currency); Asia-Pacific grew 3.2%
The STELARA problem in one number: its decline alone dragged worldwide operational growth down ~6.2 points. Without STELARA’s collapse, J&J would have posted ~12% operational growth. That’s the biosimilar cliff in action.
Margins: gross margin dipped to 67.9% ↘️ (from 69.1%) as STELARA’s high-margin revenue disappeared and tariff/currency headwinds hit MedTech. R&D fell to $14.7B (15.6% of revenue ↘️ from 19.4%) — partly because 2024 included a $1.25B one-time IPR&D charge.
Cash machine: operating cash flow hit $24.5B ↗️. The company paid $12.4B in dividends, bought back $6B in stock, and still spent $17.5B on acquisitions. Not a typo.
The talc wildcard: net earnings jumped to $26.8B in 2025 vs. $14.1B in 2024 — but ~$7B was a one-time reversal of talc litigation reserves after a Texas bankruptcy court dismissed J&J’s proposed settlement. Normalize for that, and underlying earnings growth is solid but less dramatic.
Key Takeaway: J&J generates extraordinary cash flows, but headline earnings are noisy — strip out the talc reversal and you see a healthy business absorbing a major patent cliff with impressive resilience.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Undervalued (with appropriate asterisks)
Scenario | Fair Value | vs. Current Price (~$253) |
|---|---|---|
Conservative (WACC 5.1%, TGR 2.5%) | $385 | +56% ↗️ |
FMP Model (~8% WACC) | $292 | +18% ↗️ |
Optimistic (WACC 4.9%, TGR 3.5%) | $676 | +174% ↗️ |
Key assumptions:
J&J’s beta is an unusually low 0.23 — it barely moves with the market, mathematically producing a low cost of capital (~5-5.5% WACC)
Normalized free cash flow margins of ~21-23% on $94B+ revenue = massive cash generation
Terminal growth of 2.5-3.0% is reasonable for a global healthcare franchise with 63 years of dividend growth
The wide range reflects DCF’s sensitivity to WACC — small discount-rate changes create huge terminal-value swings. The market appears to price J&J at roughly a 6-6.3% WACC, implying modest skepticism about long-term growth.
One-line take: at $253, you’re buying one of the most durable healthcare franchises on earth at an apparent discount — if you believe the oncology pipeline can offset patent cliffs.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
DARZALEX becomes a $20B+ franchise before its 2029 cliff, and TREMFYA + CAPLYTA fill the STELARA void
Oncology pipeline delivers — CARVYKTI, RYBREVANT/LAZCLUZE, and the newly acquired Halda RIPTAC platform generate meaningful revenue by 2028-2030
MedTech Cardiovascular (Shockwave + Abiomed) sustains 10%+ growth as aging populations drive procedure volumes
Bear Case 🐻
Patent cliff cascade — DARZALEX loses exclusivity in 2029 and the pipeline can’t compensate, creating a multi-year earnings trough
Talc litigation resurfaces — with the bankruptcy path closed, J&J faces 74,000+ plaintiffs in the tort system; adverse verdicts could dwarf the $3.4B reserve
Acquisition indigestion — $32B+ spent in two years (Intra-Cellular, Shockwave, Halda) is a lot to integrate; net debt jumped to $27.8B ↘️
The Bottom Line: J&J has been declared dead or disrupted roughly 47 times in 137 years and keeps cashing dividend checks. The STELARA cliff was real and painful, but the oncology franchise is genuinely impressive. Talc litigation is the wild card that keeps lawyers employed and investors nervous. For long-term investors who can stomach near-term noise, the price looks attractive.
Layer 6: What to Watch 👀
DARZALEX sales trajectory — if growth slows below 10% annually before 2028, the patent-cliff math gets scary. Watch quarterly reports.
TREMFYA’s immunology takeover — can it realistically replace STELARA’s $10B peak? It’s at $5.2B, growing 40%. Track whether it’s winning new patients or just retaining old ones.
Talc litigation developments — Daubert motions in the MDL (expected H1 2026) will signal whether J&J’s scientific defense holds. A bad ruling could reignite reserve charges.
DePuy Synthes separation — announced October 2025, targeting 18-24 months. Watch for structure (spin-off vs. sale) and whether it unlocks MedTech value.
CAPLYTA ramp — acquired for $14.5B in April 2025, generating $700M in ~9 months. Needs a clear path to $2B+ to justify the price tag.
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.